Affiliation:
1. Xuanwu Hospital Capital Medical University
2. Beijing Institute of Radiation Medicine
3. Fifth Medical Center, Chinese PLA General Hospital
4. Department of Disease Control and Prevention
5. The Brain Science Center, Beijing Institute of Basic Medical Sciences
Abstract
Abstract
Pancreatic cancer is one of the most fatal cancers in the world. A growing number of studies have begun to demonstrate that mitochondria play a key role in tumorigenesis.Our previous study reveals that NDUFS2 (NADH: ubiquinone oxidoreductase core subunit S2), a core subunit of the mitochondrial respiratory chain complex I, is unregulated in Pancreatic adenocarcinoma (PAAD). However, its role in the development of PAAD remains unknown. Here, we showed that NDUFS2 played a critical role in the survival, proliferation and migration of pancreatic cancer cells by inhibiting mitochondrial cell death. Additionally, bioinformatics analysis in clinical samples indicated that the expression of NDUFS2 was positively correlated with a deubiquitinases, OTUB1. Overexpression of OTUB1 increased NDUFS2 expression at the protein level, while knockdown of OTUB1 restored the effects in vitro. Accordingly, overexpression and knockdown of OTUB1 phenocopied those of NDUFS2 in pancreatic cancer cells, respectively. Mechanically, NDUFS2 was deubiquitinated by OTUB1 via K48-linked polyubiquitin chains, resulted in an elevated protein stability of NDUFS2. Moreover, the growth of NDUFS2-overexpressed pancreatic cancer xenograft tumor was promoted in vivo, while the NDUFS2-silenced pancreatic cancer xenograft tumor was inhibited in vivo. In conclusion, we revealed that OTUB1 increased the stability of NDUFS2 in PAAD by deubiquitination, and this axis plays a pivotal role in pancreatic cancer genesis and development.
Publisher
Research Square Platform LLC
Reference34 articles.
1. Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States;Rahib L;Cancer Res,2014
2. Siegel RL, Miller KD, Fuchs HE and Jemal A. Cancer Statistics, 2021. 2021; 71: 7–33.
3. Phase II Trial of Postoperative Adjuvant Gemcitabine and Cisplatin Chemotherapy Followed by Chemoradiotherapy with Gemcitabine in Patients with Resected Pancreatic Cancer;Lee KH;Cancer Res Treat,2021
4. Cancer statistics, 2020;Siegel RL;CA Cancer J Clin,2020
5. Safety and efficacy of preoperative or postoperative chemotherapy for resectable pancreatic adenocarcinoma (PACT-15): a randomised, open-label, phase 2–3 trial;Reni M;Lancet Gastroenterol Hepatol,2018